An American College of Surgeons National Quality Improvement Collaborative to Understand Barriers to Completion of Cancer Treatment Study population consisted of 10,717 ... type (de novo [presence of ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

His wife convinced him to go for a "man check" which eventually led to a prostate cancer diagnosis, a move from New Zealand to Australia and a place in a world-first medical trial. Subscribe for FREE ...

“Survival rates in metastatic castration-resistant prostate cancer are poor due to the advanced and aggressive stage of the disease. Today’s results demonstrate the potential for TALZENNA in ...

Early prostate ... with prostate cancer. BPH usually affects older adults. In fact, it affects around 50% of males ages 60 and older. Treatment often involves a combination of lifestyle changes ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate ... in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status ...

“Survival rates in metastatic castration-resistant prostate ... breast cancer. TALZENNA in combination with XTANDI was approved by the U.S. Food and Drug Administration (FDA) for the treatment ...

a novel biopsy test which provides improved estimation of a patient’s risk of prostate cancer recurrence and allows for optimal treatment selection. Currently, the US is the major market for ...